drugset / Trial / NCT00213577

NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder

NCT00213577

Phase 2 Terminated 80 enrolled University Hospital, Rouen
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.

Timeline

Start
2003-12
Primary completion
2007-09
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Type A Botulinum toxin Unknown 500 iu Other
Subject Type A Botulinum toxin Unknown 750 iu Other

Indications